Tumor resident Tregs express high levels of unique signature genes Ccr8, Tnfrsf8, Cxcr3, and Smasn1 (143, 144), which might serve as valuable targets for tumor immunotherapy. This evidence concerns the gene CCR8 and neoplasm.